Alder looks to raise $115M-plus; Radius touts PhIII osteoporosis data;

@FierceBiotech: New special report: Best and worst 2014 biotech performers on Wall Street. Feature | Follow @FierceBiotech

@JohnCFierce: Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact. Article | Follow @JohnCFierce

@DamianFierce: $ABBV's Viekira pitch includes this boomer-focused quiz thing on Facebook, featuring rotary phones and candy paper. More | Follow @DamianFierce

> Seattle-based Alder Biopharmaceuticals is out to raise more than $115 million in a secondary offering. Story

> Waltham, MA-based Radius Health says it garnered positive top-line data from its Phase III study of abaloparatide-SC for the reduction of fractures in postmenopausal osteoporosis. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Asante files for $45M IPO to market cheap, easy insulin pump. More | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ interview comments: NIH launches crowdsourcing challenge to commercialize its neurological medical devices. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out @FierceBiotech's latest special report for this year's biotech winners and losers. More | Follow @EmilyWFierce

> Study: Devices for obstructive sleep apnea could improve symptoms of depression. Article

> Trio of med techs file IPOs to raise a total of up to almost $140M. Story

Pharma News

@FiercePharma: Pfizer turns the sex talk toward 50-ish women with menopause awareness push. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout? Article | Follow @CarlyHFierce

> With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda. More

> Justice Department sues Omnicare for rigging kickbacks with Abbott. Report

> Want to place biopharma bets for 2015? JPM flags Alexion, BioMarin and Bristol-Myers. Article

> SEC says insider made $10M on Abbott, CFR deal. Story

Biotech Research News

> Northwestern team claims they have found the right way to ID Alzheimer's early on. Report

> New research points to a key driver--and new drug target--behind hepatitis infections. More

> Brown U dean points to a possible suspect driving metastasis. Article

> Stem cell investigator resigns in wake of controversy. Item

> J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration. Story

Pharma Manufacturing News

> Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax. Item

> Bayer picks Cardinal Health to manufacture Xofigo in U.S. News

> Fujifilm becomes part of U.S. pandemic defense with deal for Kalon Biotherapeutics. More

> India warns Egyptian companies claiming to have Sovaldi for sale. Article

> Fresenius closes out recall started two years ago. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.